Introduction

15
Human herpesvirus-6A and -6B (HHV-6A and HHV-6B) are widespread with a 16 seroprevalence over 90% in adults. Primary infection is associated with a usually benign skin 17 rash in infants (exanthema subitum), but reactivation from latency can lead to severe disease, HHV-6A and HHV-6B in in vitro studies (5) . Their clinical use for HCMV reactivation in 1 transplant recipients could concomitantly reduce HHV-6 reactivation. It has been observed in 2 several studies where liver transplant patients on (val)ganciclovir prophylaxis had a lower 3 incidence of HHV-6 infection compared with those who received acyclovir or no prophylaxis 4 (6-8). For the therapy of HHV-6 infections and related symptoms, a few case reports and 5 small patient series suggested an impact of antiviral drugs on the viral load and the resolution 6 of clinical signs but it is not always reliably effective and the success rate was estimated to 7 approximately 60% (3,4,9). Because of the lack of controlled trials proving their benefit, none 8 is officially approved for the prophylaxis, the preemptive therapy and the treatment of HHV-6 9 infections, except a recommendation in case of encephalitis, and no specific dosage and 10 duration are established. Furthermore, they exhibit toxicity to the bone marrow or kidneys 11 requiring appropriate use in the clinical context. Importantly, an efficient cellular immunity, 12 possibly restored by a reduction in the degree of immunosuppression, remains essential to 13 control active infections and improve clinical symptoms (9,10).
14
In parallel to the usual infection, the genome of HHV-6A and -6B is covalently integrated into 15 a chromosome of all germinal and somatic cells in approximately 1% of the world population 16 and is vertically transmitted in a Mendelian manner (iciHHV-6 for inherited chromosomally 17 integrated HHV-6, also called ciHHV-6) (11). The presence of iciHHV-6 is therefore always 18 associated with high viral loads in patient samples, over 5.5 log 10 copies per mL of whole 19 blood or at least one genome copy per cell, and can be confounded with a high HHV-6 20 reactivation leading to unnecessary treatments. Indeed, it was first assumed to be an exclusive 21 latent form, until in vitro and in vivo studies evidenced that viral expression could occur (11).
22
The clinical impact on iciHHV-6 carriers generally appears to be limited, with a statistical 23 association with angina pectoris (12) . However, the reactivation of an iciHHV-6A with negative for CMV by immunostaining and PCR, but highly positive for HHV-6 by PCR (4.8
12
-8.4 log 10 copies/10 6 cells) (Fig.1) . DNA from saliva and bronchoalveolar lavage were also 
16
GVHD and acute liver rejection were excluded by liver biopsy at day 32 and post-mortem.
17
Since HSV-1 and EBV viremia were positive at day 38 ( Fig.1) , immunosuppressive therapy 18 was reduced. Prednisolone dose was decreased to 10 mg/day, MMF was interrupted and treatments (300 -400 ng/mL). The patient was treated with foscarnet (6 g/day) from day 35 to 21 day 47 post-transplantation with no effect on viral load (Fig.1) , before being discontinued due 22 to severe hypokalemia. It was replaced by ganciclovir (450 mg twice a day) from day 47 to 23 day 62, before pancytopenia led to another switch to foscarnet (6 g/day). Further evolution of 24 the patient's condition was characterized by persistence of pancytopenia, increased 25 disorientation, profuse diarrhea (exudative enteropathy), and several episodes of septic shock.
6
Last one, at day 96, was due to an ischemic cholangitis (transaminases > 10N). Despite 1 treatment with noradrenaline and antibiotics, the patient died from multiple organ failure 98 2 days after transplantation.
3
We quantified the HHV-6 DNA from various compartments of the recipient and donor to 4 identify the source of the HHV-6 infection using a real-time PCR method developed by Gautheret-Dejean (1). Viral loads in the recipient varied from one compartment to another. It 6 was less than 4 log 10 cop/10 6 cells in whole blood and negative in the native liver, excluding 7 the presence of iciHHV-6 in the patient. By contrast, the viral loads were 7.5 and 6.9 log 10 8 copies/10 6 cells in the liver and spleen of the donor, respectively, suggesting the presence of to the recipient, followed by reactivation of this strain in various tissues.
23
As antiviral treatments with ganciclovir or foscarnet failed to decrease viral loads and
24
improve clinical symptoms, resistance mutations were searched in the relevant viral genes,
25
U38 (DNA polymerase) and U69 (phosphotransferase). We sequenced DNA from the donor 26 spleen, the transplanted liver, a colon biopsy, and saliva from the recipient before (day 32) known to be resistance mutations, suggesting that this iciHHV-6A strain was sensitive to 7 antiviral drugs. Overall, the sequence identity between three genes (7.2 kb) of the donor and recipient samples consistent with strong reactivation of the iciHHV-6A present in the transplanted liver.
13
Increased allograft rejection among patients with HHV-6 reactivation in the transplanted 14 organ have been described, resulting from boosted immune system and leucocytes infiltration 15 or syncytial giant cell hepatitis (1, 4, 26) . Such specific histopathology was not observed here, 16 neither were signs of acute liver rejection. The most likely cause for fatal outcome here is the 17 reactivation of iciHHV-6 from the graft and infection of the brain, digestive tract and saliva.
18
This was associated with encephalopathy, profuse diarrhea, and followed by a series of septic 
